Related Experiment Video

Updated: Jun 5, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy

Yoh Dobashi1, Shinichiro Koyama, Yoshihiko Kanai

  • 1Department of Pathology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Frontiers in Bioscience (Landmark Edition)
|January 4, 2011
PubMed

Insights

New lung cancer therapies targeting the epidermal growth factor receptor (EGFR) show promise but face limitations. Understanding EGFR signaling pathways is crucial for developing more effective cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer prognosis remains poor despite advances in oncology.
  • Tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR), such as gefitinib and erlotinib, offer new therapeutic avenues.
  • EGFR mutations correlate with sensitivity to these drugs, enabling targeted therapy.

Purpose of the Study:

  • To review EGFR abnormalities and downstream signaling in lung cancer.
  • To discuss molecular mechanisms underlying response to EGFR blockade.
  • To identify potential therapeutic targets for improved lung cancer treatment.

Main Methods:

  • Review of preclinical data.
  • Analysis of clinicopathological aspects.
  • Summarization of molecular mechanisms in lung cancer.

Main Results:

  • EGFR inhibitors demonstrate efficacy but are limited by side effects and drug resistance.
  • Specific EGFR mutations influence treatment sensitivity.
  • Downstream signaling pathways are critical for therapeutic response.

Conclusions:

  • Further research into EGFR downstream signaling is essential for overcoming treatment limitations.
  • Targeting key signaling factors may lead to more effective lung cancer therapies.
  • A deeper understanding of molecular mechanisms can guide rational clinical strategies.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...